AN ILLUSTRATED READING-ROOM · A THREE-PEPTIDE BLEND
GLOW peptide is a three-part research blend of GHK-Cu, BPC-157 and TB-500.
Three peptides, three literatures, one reading-room. We set the constituents down as study plates, annotate the combination thesis, and keep the regulatory record in the margin — with every quantitative claim cited.
What GLOW peptide is
GLOW peptide is a three-part research blend of GHK-Cu, BPC-157 and TB-500 — not a single molecule, and not an approved drug. It is a co-formulated combination of three distinct research peptides, drawn together because their published mechanisms point at the same target: tissue repair and skin renewal.
The three constituents do different work. GHK-Cu — the copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine, INCI name Copper Tripeptide-1 — is a matrix-remodeling, collagen-stimulating copper peptide and the skin lead of the blend. BPC-157 is a synthetic stable pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a gastric body-protection protein; in research it is cytoprotective and pro-angiogenic. TB-500 is an acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4, studied for cell migration and reduced scarring.
There are no controlled clinical trials of the glow blend itself. The evidence base is the literature on each constituent peptide, plus the mechanistic rationale for combining them [1][3][5]. That distinction runs through every page here: what the published studies establish at the constituent level, and what is asserted about the trio without having been tested as a trio.
Exact ratios are formulation-specific and not standardized; a commonly cited research-label convention is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, which is a supplier labeling convention rather than a clinically validated dose [9]. The related KLOW blend adds KPV; the Wolverine blend is BPC-157 + TB-500 only.
GLOW peptides: the three constituents
The glow peptides resolve to three named molecules, each with its own role in the combination thesis and its own machine identifiers on the record.
GHK-Cu (Copper Tripeptide-1, CAS 89030-95-5, MW ~402.9 Da) carries the matrix-and-collagen leg. The free GHK sequence occurs within human type I collagen and circulates in plasma, declining with age; as the copper complex it stimulates dermal fibroblast synthesis of collagen, elastin and glycosaminoglycans [1][2]. BPC-157 (MW ~1419 Da) carries the cytoprotective and pro-angiogenic leg, up-regulating VEGFR2 and accelerating connective-tissue healing in animal models [3][4]. TB-500 (MW ~889 Da, parent: thymosin beta-4, gene TMSB4X) carries the cell-migration and anti-scarring leg, sequestering G-actin to drive cell movement [5][6].
The identifiers matter because the same names get used loosely online. "TB-500" in commerce is the Ac-LKKTETQ heptapeptide, but most of the efficacy data uses full-length thymosin beta-4 — it is not established that the fragment reproduces the parent protein's effects [6]. See GHK-Cu, BPC-157 and TB-500 constituents below in the comparison register, and the research on the GLOW blend for the mechanism in depth.
GLOW as a peptide stack vs the KLOW and Wolverine blends
As a glow peptide stack, GLOW sits in a small family of clinic- and supplier-formulated combinations that share the BPC-157 + TB-500 repair pairing and differ at the edges. GLOW is GHK-Cu + BPC-157 + TB-500 — the addition of the copper tripeptide is what tilts it toward skin and aesthetics. The KLOW blend adds KPV, an anti-inflammatory tripeptide, to the GLOW trio. The Wolverine blend strips back to BPC-157 + TB-500 only, the pure tissue-repair pairing without the skin lead.
None of these blends has been tested as a unit in a controlled human trial; the family is best understood as a set of mechanistic recipes rather than validated products. The combination rationale for GLOW specifically is complementary coverage — a matrix-building signal, a vascular signal and a cell-mobility signal — which is a thesis about mechanism, not a demonstration of synergy [1][3][5].
What the constituent literature shows
The strongest individual findings sit at the constituent level and are worth surfacing plainly. In a rat full-thickness wound model, thymosin beta-4 — the parent of TB-500 — increased re-epithelialization by 42% over saline controls at day 4 and 61% at day 7, and as little as 10 pg stimulated cell migration two- to three-fold [5]. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures, and stimulated tendocyte outgrowth in vitro [3]. A canonical skin-regeneration review establishes GHK-Cu's matrix-synthesis profile — collagen, dermatan sulfate, chondroitin sulfate and decorin — and its cosmetic improvements in skin elasticity, density and firmness [1].
Those are real results, and they are also constituent-level and largely preclinical. A 2026 Sports Medicine review that names BPC-157, TB-500 and GHK-Cu together concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce and the potential for harm is real [10]. That is the honest frame for the whole blend: promising parts, an untested whole.
Dig deeper in the research on the GLOW blend, see the skin and aesthetics record on GLOW peptide for skin research, or read the frequently asked questions about GLOW.
What is GLOW peptide?
GLOW peptide is a non-standardized multi-peptide research blend, most commonly GHK-Cu + BPC-157 + TB-500, formulated by clinics and suppliers rather than a single approved drug. The name resolves consistently to that trio across consumer and clinic sources, but ratios and purity vary by source and the blend has never been a single regulated product [9].
What does the GLOW peptide do?
Its three constituents are studied for complementary tissue-repair and skin-renewal mechanisms: matrix remodeling and collagen synthesis (GHK-Cu), angiogenesis and cytoprotection (BPC-157), and cell migration with reduced scarring (TB-500). These are constituent-level research roles drawn from the published literature, not a demonstrated effect of the blend itself [1][3][5].
What does GLOW peptide have in it?
Most commonly GHK-Cu (a collagen-stimulating copper peptide), BPC-157 (a body-protection pentadecapeptide) and TB-500 (a thymosin beta-4 fragment). Exact ratios are formulation-specific and not standardized; a commonly cited research-label convention is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, a supplier labeling convention rather than a validated dose [9].
What peptides are in the GLOW blend?
GHK-Cu, BPC-157 and TB-500. The related KLOW blend adds KPV, a fourth tripeptide; the Wolverine blend is BPC-157 + TB-500 only, without the GHK-Cu skin lead. GLOW is the three-peptide configuration whose copper tripeptide gives it its skin-and-aesthetics emphasis [9].